- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 322
Flavin flaunts return to university venturing
Portal Innovations will target biomedical spinouts from across the Midwest under the direction of ex-UChicago innovation veteran John Flavin.
Mar 9, 2020Woodford sounds out appetite for $655m fund
Neil Woodford could return to the stage with a bid for some of his old assets should ongoing talks with unnamed UK-based institutional investors and wealth managers succeed.
Mar 9, 2020Corporate venturing deal net: 2-6 March 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Mar 6, 2020Culture Biosciences gets $15m funding reaction
MIT Media Lab-affiliated E14 Fund has invested in the biomanufacturing software provider as part of a series A round led by Cultivian Sandbox Ventures.
Mar 6, 2020Recipharm returns for latest Cinclus round
Cinclus Pharma has lured back corporate venturing unit Recipharm Venture Fund for a $26.4m round that will fund a phase 2 study for its GERD therapy candidate.
Mar 6, 2020GV helps pump series C funding into Element
The wearable defibrillator developer, founded by Stanford adjunct professor Uday Kumar, has raised more than $145m that will support the launch of its lead product.
Mar 6, 2020Oric originates IPO filing
The Taiho Ventures, Memorial Sloan and Hartford HealthCare Endowment-backed cancer drug developer has filed to raise up to $86.3m.
Mar 5, 2020Novartis helps plant $100m in Pliant
Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.
Mar 4, 2020GV helps pump series C funding into Element
The wearable defibrillator developer revealed GV is an existing investor as it raised more than $145m that will support the launch of its lead product.
Mar 4, 2020Novartis helps plant $100m in Pliant
Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.
Mar 4, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


